Newron Pharmaceuticals SpA banner

Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 18.3 CHF -2.03% Market Closed
Market Cap: CHf366.2m

Intrinsic Value

The intrinsic value of one NWRN stock under the Base Case scenario is hidden CHF. Compared to the current market price of 18.3 CHF, Newron Pharmaceuticals SpA is hidden .

NWRN Intrinsic Value
HIDDEN
Show

Valuation History
Newron Pharmaceuticals SpA

Intrinsic Value History
Dive into the past to invest in the future

NWRN looks overvalued. Yet it might still be cheap by its own standards. Some stocks live permanently above intrinsic value; Historical Valuation reveals whether NWRN usually does or if today's premium is unusual.

Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Show Historical Valuation
What is Valuation History?
Ask AI Assistant
What other research platforms think about NWRN?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is NWRN valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Newron Pharmaceuticals SpA.

Explain Valuation
Alternatives to NWRN

Fundamental Analysis

Financials
Efficiency

Earnings Waterfall
Newron Pharmaceuticals SpA

Wall St
Price Targets

Dividends

Newron Pharmaceuticals SpA
does not pay dividends
Shareholder Yield
Buyback Yield
HIDDEN
Debt Paydown Yield
HIDDEN

Competitive Landscape

What is the Intrinsic Value of one NWRN stock?

The intrinsic value of one NWRN stock under the Base Case scenario is hidden CHF.

Is NWRN stock undervalued or overvalued?

Compared to the current market price of 18.3 CHF, Newron Pharmaceuticals SpA is hidden .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett